Compare Fiverr International Ltd (FVRR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Neurocrine Biosciences Inc — how do they compare? Fiverr International Ltd trades at $8.63 (market cap $310.61M), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 46.2× Fiverr International Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FVRR | NBIX | |
|---|---|---|
Market Cap | $310.61M | $14.36B |
Volume | 381,459 | 1,237,180 |
Sector | Media | Health |
52-Week High | $23.60 | $185.50 |
52-Week Low | $8.47 | $123.10 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $63.00M | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.50, up 0.35% on the day, but has faced recent pressure with two consecutive quarterly earnings misses. The stock shows a bearish technical signal, with moving averages indicating a downtrend, while fundamentals reveal modest revenue growth to $430.91M in 2025 and a net income margin of 4.86%. Recent news highlights AI disruption compressing demand for freelance services, contributing to a 15% stock slump post-Q2 results.
The outlook remains cautious; while valuation ratios like P/E of 10.49 and P/S of 0.74 appear attractive, risks from AI competition and lowered 2026 guidance weigh on sentiment. Analyst consensus is a 'Hold' with a $10.50 price target, suggesting limited upside amid operational headwinds. Investors should balance cheap valuations against execution risks in a shifting gig economy.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
